Evidence map›Paper›PMID 30939847›Full record

ReviewGenes2019

Pharmacogenetics in the Treatment of Cardiovascular Diseases and Its Current Progress Regarding Implementation in the Clinical Routine.

Cristina Lucía Dávila-Fajardo, Xando Díaz-Villamarín, Alba Antúnez-Rodríguez, Ana Estefanía Fernández-Gómez, Paloma García-Navas, Luis Javier Martínez-González, José Augusto Dávila-Fajardo, José Cabeza Barrera

Full text readReview
In one paragraph

Review in Genes, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Coumarin-piperazine derivatives as biologically active compounds.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2020
    Review
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Cristina Lucía Dávila-FajardoDepartment of Clinical Pharmacy, San Cecilio University Hospital, Institute for Biomedical Research, ibs.GRANADA, 18016 Granada, Spain. cristinal.davila.sspa@juntadeandalucia.es.
Xando Díaz-VillamarínDepartment of Clinical Pharmacy, San Cecilio University Hospital, Institute for Biomedical Research, ibs.GRANADA, 18016 Granada, Spain. xandodv@gmail.com.
Alba Antúnez-RodríguezGenomics Unit, Centro Pfizer-Universidad de Granada-Junta de Andalucía de Genómica e Investigación Oncológica (Genyo), 18016 Granada, Spain. albantunez@gmail.com.
Ana Estefanía Fernández-GómezDepartment of Clinical Pharmacy, San Cecilio University Hospital, Institute for Biomedical Research, ibs.GRANADA, 18016 Granada, Spain. estefania_fergo@hotmail.com.
Paloma García-NavasDepartment of Clinical Pharmacy, San Cecilio University Hospital, Institute for Biomedical Research, ibs.GRANADA, 18016 Granada, Spain. palomichi_96@hotmail.com.
Luis Javier Martínez-GonzálezGenomics Unit, Centro Pfizer-Universidad de Granada-Junta de Andalucía de Genómica e Investigación Oncológica (Genyo), 18016 Granada, Spain. luisjavier.martinez@genyo.es.
José Augusto Dávila-FajardoEnglish Department, Official Language School Leganes, Madrid, Spain. josehood11@hotmail.com.
José Cabeza BarreraDepartment of Clinical Pharmacy, San Cecilio University Hospital, Institute for Biomedical Research, ibs.GRANADA, 18016 Granada, Spain. jose.cabeza.sspa@juntadeandalucia.es.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

There is a special interest in the implementation of pharmacogenetics in clinical practice, although there are some barriers that are preventing this integration. A large part of these pharmacogenetic tests are focused on drugs used in oncology and psychiatry fields and for antiviral drugs. However, the scientific evidence is also high for other drugs used in other medical areas, for example, in cardiology. In this article, we discuss the evidence and guidelines currently available on pharmacogenetics for clopidogrel, warfarin, acenocoumarol, and simvastatin and its implementation in daily clinical practice.

Indexed as

PharmacogeneticsAcenocoumarolAnticoagulantsAryl Hydrocarbon HydroxylasesCardiovascular DiseasesClopidogrelCytochrome P-450 CYP2C9Guidelines as TopicHumansPrecision MedicineSimvastatinWarfarinAcenocoumarolAnticoagulantsAryl Hydrocarbon HydroxylasesClopidogrelCytochrome P-450 CYP2C9SimvastatinWarfarinacenocoumarolclopidogrelpharmacogeneticswarfarin

Identifiers

PMID30939847
PMCPMC6523655

What OpenQuestion holds

Textfull text, public
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.